Long-term safety of adalimumab for patients with moderate-to-severe hidradenitis suppurativa

Tzanetakou, Vassiliki; Stergianou, Dimitra; Giamarellos‐Bourboulis, Evangelos J.

doi:10.1080/14740338.2020.1734560

Cited by 8 publications

(9 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This has provided great insights in AD [47,48] and can do the same in HS given that Adalimumab is currently licensed for the treatment of HS, and many other monoclonal antibodies are currently in late-stage clinical trials. [8,[49][50][51] One limitation of the current studies is a dearth of information on strain-specific factors present in bacteria on HS skin lesions. Strain level tracking would require a combination of culture and whole-genome sequencing.…”

Section: Summary and Future Directionsmentioning

confidence: 99%

A systematic review and critical appraisal of metagenomic and culture studies in hidradenitis suppurativa

Williams

Frew

Krueger

2020

Experimental Dermatology

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic inflammatory skin disease with still largely unknown pathogenesis. While infectious organisms have been identified in lesions of the disease since the 1980s, questions remain over the role that bacteria and microbiome play. Recent studies using 16S ribosomal RNA gene sequencing and larger culture-based studies have begun to paint a clearer picture of the microbial world of HS. With this systematic review, we summarize all the work that has been done to date in HS bacteriology, analyse potential pitfalls and limitations of the current studies, and address future directions of investigation. This systematic review attempted to collate and analyse all bacteriology studies done to date. This review was prospectively registered with PROSPERO ( 1670769) performed in line with the PRISMA checklist. Twenty two studies were identified comprising 862 individual HS patients for culture studies and 206 HS patients for 16S rRNA gene sequencing studies. Methodology tended to be varied, with different sampling, culturing and sequencing methods as well as amount of analysis and stratification of patients. Bacteria identified as elevated in HS lesions in sequencing studies as well as grown from HS lesions in culture studies are identified and discussed. These primarily included the anerobic Gram-negative bacilli Prevotella, Porphyromonas and Fusibacterium, the Gram-positive bacilli Corynebacterium, and the Gram-positive cocci Staphylococcus, Streptococcus and Parvimonas. Potential interactions, as well as work in other disease models with related bacteria are also discussed. Areas of further investigation include in vitro studies of interactions between bacteria and keratinocytes, gut and oral microbiome studies and deep sequencing studies for virulence and phage factors.

show abstract

Section: Summary and Future Directionsmentioning

confidence: 99%

A systematic review and critical appraisal of metagenomic and culture studies in hidradenitis suppurativa

Williams

Frew

Krueger

2020

Experimental Dermatology

View full text Add to dashboard Cite

show abstract

“…Furthermore, this therapy theoretically increases susceptibility to other pathogens such as bacteria ( Listeria monocytogenes or Salmonella spp.) and viruses (hepatitis B virus, VZV, and human polyomavirus John Cunningham) [ 7 , 12 ].…”

Section: Discussionmentioning

confidence: 99%

“…TNF-α increases endothelial permeability, enhances leukocyte migration, and activates neutrophils and eosinophils functionally. Consequently, it is involved in a range of adaptive immune responses, including granuloma formation, phagosome development, macrophage activation and differentiation, and the immune response against viral pathogens [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Cerebral Tuberculosis After Therapy With Adalimumab for Hidradenitis Suppurativa: A Rare Case

Martins,

Rodrigues,

Fonseca Oliveira

et al. 2024

Cureus

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with limited therapeutic options. Adalimumab, an anti-tumor necrosis factor-alpha (TNF-α) monoclonal antibody, was the first biological agent approved for the treatment of moderate to severe HS. Tuberculosis (TB) is a highly prevalent global public health problem, affecting individuals worldwide. Continuous immunosuppression from TNF-α treatment increases the risk of TB development. Isolated neurotuberculosis, in the absence of other symptoms, emerges as a rarely observed infection pattern in such patients. We present a case of a 23-year-old woman with severe HS undergoing treatment with adalimumab. After two years, she developed a pronounced occipital tension headache, constant nausea, and persistent fever. The patient's latent TB status was unknown without annual screening. Subsequent magnetic resonance imaging revealed a lesion in the cerebellar vermis. Immunosuppressive therapy was suspended and an etiological study was conducted; the only positive result was the interferon-gamma release assay. Empirically, antituberculosis treatment and prednisolone were initiated, leading to clinical and neurological improvement. After one year of treatment, symptoms resolved without neurological sequelae. This case highlights the importance of vigilant monitoring before, during, and after immunosuppressive treatment. Early recognition, discontinuation of anti-tumor necrosis factor medications, and appropriate management of TB are crucial to prevent complications.

show abstract

“…The literature search suggests limited safety concerns with long-term treatment provided patients are screened for infections, tuberculosis, and malignancy before the initiation of treatment [43,44]. If antibiotics do not provide a satisfactory response, adalimumab may be considered for the treatment of HS [10].…”

Section: Biologicsmentioning

confidence: 99%

Efficacy and Toxicity of Classical Immunosuppressants, Retinoids and Biologics in Hidradenitis Suppurativa

Das

Daveluy

Kroumpouzos

et al. 2022

JCM

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic inflammatory disorder of the apocrine glands characterized by recurrent episodes. Although several therapies exist, none is completely curative. Several immunosuppressives have been studied with encouraging results and targeted approaches. In this review, we highlight the various immunosuppressives used in this condition along with their salient features to enable physicians to choose the correct therapy for their patients. The search of the peer-reviewed literature included clinical trials, scientific reviews, case series, case reports, and guidelines. The literature was identified from electronic databases (MEDLINE and PubMed) through November 2021; additional articles were included from the references of the identified articles.

show abstract

Long-term safety of adalimumab for patients with moderate-to-severe hidradenitis suppurativa

Cited by 8 publications

References 73 publications

A systematic review and critical appraisal of metagenomic and culture studies in hidradenitis suppurativa

A systematic review and critical appraisal of metagenomic and culture studies in hidradenitis suppurativa

Cerebral Tuberculosis After Therapy With Adalimumab for Hidradenitis Suppurativa: A Rare Case

Efficacy and Toxicity of Classical Immunosuppressants, Retinoids and Biologics in Hidradenitis Suppurativa

Contact Info

Product

Resources

About